At present, antibody-based therapies are undergoing a renaissance In the wake of being created and afterward to a great extent relinquished in the twentieth century, many antibody preparations are presently in clinical use Interest in utilizing antibodies to treat irresistible infections is now being fuelled by the wide dissemination of drug-resistant pathogens, the rise of new pathogens, the overall inefficacy of medications in immunocompromised hosts and the fact that antibody-based treatments are the main way to give prompt resistance against biological weapons Given the requirement for new drug therapies and numerous ongoing innovative advances in the field of immunoglobulin research, there is generous affirmation concerning improved applications of antibody-based therapy for the anticipation and treatment of infectious diseases The advent of new pathogens for which there is no compelling treatment alternative has redrawn the regard for the usefulness of convalescent plasma To be sure, convalescent plasma can be an alternate and quick remedial choice in outbreaks of infectious diseases such as Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome (SARS), H1N1 flu, H5N1 flu, Ebola, Poleomyelitis, Measles and COVID-19 Copyright © Journal of Global Trends in Pharmaceutical Sciences
The use of convalescent plasma as a novel treatment in pandemic disease: A review